Skip to main content
Humalog Home
  • Prescribing Information
  • Patient Prescribing Information
  • Instructions for Use
Menu closed
Humalog Home
  • Prescribing Information
  • Patient Prescribing Information
  • Instructions for Use
Globe Loading... Reveal available languages
  • House For Healthcare Providers
      • Efficacy
      • Device Options
      • Self Titration Dosing
    • Humalog U-200
      • PK/PD Data
      • Dosing Volume
    • Humalog Mixes
    • Savings & Support
  • For Consumers
Ask Lilly

We're here to help.

Phone Call:
1-800-LillyRx
(1-800-545-5979)
Link Visit Lilly Medical (HCP)
Question Submit a Question
Expand contact lilly

Patients can start and stay on Humalog U-200 KwikPen as their insulin needs increase*

*Option for patients who require >20 units of mealtime insulin/day.

Humalog U-200 KwikPen insulin injector

Bioequivalence – with half the volume

Humalog U-200 is bioequivalent* to Humalog U-100; therefore you should expect similar efficacy and safety as Humalog U-1001. Humalog U-200 KwikPen delivers the same dose of insulin in half the liquid volume.1

Humalog U-200 was bioequivalent* to Humalog U-100 after subcutaneous administration of a single 20-unit dose in healthy subjects. Time to maximum concentration was also similar between formulations.

Pharmacokinetic properties between Humalog U-200 and U-100 chart

This line graph presents the pharmacokinetics of Humalog (insulin lispro) U-200 (200 units per milliliter) and Humalog (insulin lispro) U-100 (100 units per milliliter). The Y-axis shows mean free serum immunoreactive insulin concentrations ranging from 0 to 1000 picomoles per liter. The X-axis expresses time in hours after insulin lispro administration, ranging from 0 to 6 hours. Peak serum insulin concentration for U-100 was 839 picomoles per liter (standard error equals 34), occurring 1 hour after insulin administration. Peak serum insulin concentration for U-200 was 745 picomoles per liter (standard error equals 33), also occurring 1 hour after insulin administration.

*As determined by area under the curve and maximum concentration.

Pharmacodynamic properties between Humalog U-200 and U-100 chart

This line graph presents the pharmacodynamics of Humalog (insulin lispro) U-200 (200 units per milliliter), 20 units administered subcutaneously (sc) and Humalog (insulin lispro) U-100 (100 units per milliliter), 20 units administered subcutaneously (sc). The Y-axis shows the mean glucose infusion rate, with values ranging from 0 to 600 milligrams per minute. The X-axis expresses time in hours from insulin lispro dose administration, ranging from 0 to 8 hours. Insulin lispro U-100 had a peak mean glucose infusion rate of 418.4 milligrams per minute at hour 3.0, while insulin lispro U-200 had a peak mean glucose infusion rate of 415.2 milligrams per minute at hour 2.7.

Select Important Safety Information

Instruct patients to always check the insulin label before each injection to avoid medication errors. Do NOT transfer Humalog U-200 from the Humalog KwikPen to a syringe as overdose and severe hypoglycemia can occur.

Dosing Volume

Humalog U-200 and Humalog U-100 dosing volume

Delivers the same dose in half the liquid volume of Humalog U-100 KwikPen

Humalog 200 units/mL is twice the concentration of Humalog U-100 mealtime, rapid-acting insulin.

References: 1. Humalog [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC; 2015. 2. Data on file, Lilly Research Laboratories: HI20150526A.

IMPORTANT SAFETY INFORMATION

Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 are contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to these insulins or any of their excipients.

Never share a Humalog or Insulin Lispro Injection prefilled pen, cartridge, reusable pen compatible with Lilly 3 mL cartridges, or syringe between patients, even if the needle is changed. Patients using vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Due to reports of hyperglycemia and hypoglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant antidiabetic products may be needed.

Hypoglycemia: Severe hypoglycemia may be life threatening and can cause seizures or death. Hypoglycemia is the most common adverse reaction of Humalog and Insulin Lispro Injection. Monitor blood glucose and increase monitoring frequency with changes to insulin dosage, use with glucose-lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness.

Hypoglycemia Due to Medication Errors: Instruct patients to always check the insulin label before each injection to avoid medication errors. Humalog U-200 should not be transferred from the Humalog KwikPen to a syringe as overdose and severe hypoglycemia can occur.

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Humalog and Insulin Lispro Injection. If hypersensitivity reactions occur, discontinue the use of insulin and treat per standard of care until signs and symptoms resolve.

Hypokalemia: Hypokalemia may be life threatening. Insulins, including Humalog and Insulin Lispro Injection, cause a shift in potassium from the extracellular to intracellular space possibly leading to hypokalemia, which, if untreated, may result in respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia (e.g., patients using potassium-lowering medications or medications sensitive to serum potassium concentrations).

Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Thiazolidinediones (TZDs), which are PPAR-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin, including Humalog and Insulin Lispro Injection. This may lead to or exacerbate heart failure. Observe patients for signs and symptoms of heart failure and consider discontinuation or dose reduction of the PPAR-gamma agonist.

Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction: Malfunction of the insulin pump device, infusion set, or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using subcutaneous insulin infusion pumps must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.

Adverse reactions associated with Humalog and Insulin Lispro Injection include hypoglycemia, hypokalemia, allergic reactions, injection-site reactions, lipodystrophy, pruritus, rash, weight gain, and peripheral edema.

Some medications may alter glucose metabolism, insulin requirements, and the risk for hypoglycemia or hyperglycemia. Signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs. Particularly close monitoring may be required.

HI BOI SP U100 75/25 HCP ISI 01SEP2023

INDICATIONS

Humalog and Insulin Lispro Injection are rapid-acting insulin analogs indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Humalog Mix75/25 and Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are mixtures of intermediate-acting and rapid-acting human insulin analogs indicated to improve glycemic control in patients with diabetes mellitus.

Limitations of Use: The proportions of rapid-acting and intermediate-acting insulins in Humalog Mix75/25 and Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.

    • Visit LillyMedical.com
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

To speak to customer support:
Call (800) 545-5979

This site is intended for US healthcare professionals only.

Models used for illustrative purposes only. Not actual patients or healthcare providers.

PP-DB-US-0733 10/2023 ©Lilly USA, LLC 2023. All rights reserved.

Humalog®, Humalog® KwikPen®, and Humalog® Junior KwikPen® are registered trademarks of Eli Lilly and Company, its subsidiaries, or affiliates. Humalog® Mix75/25™, Humalog® Mix50/50™, Humalog® Mix75/25™ KwikPen®, and Humalog® Mix50/50™ KwikPen® and LillyDirect™ are trademarks of Eli Lilly and Company.

Terms of Use Privacy Statement Accessibility Statement Sitemap
Lilly.com